RANKL in the osteolysis of AES total ankle replacement implants

Bone

Volumn 51, Issue 3, 2012, Pages 546-552

  Koivu, H ^a   MacKiewicz, Z ^b,c,d   Takakubo, Y ^d,e   Trokovic, N ^d,f   Pajarinen, J ^f   Konttinen, Y T ^d,g,h  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c State Research Institute Center for Innovative Medicine   (Lithuania)

^d Biomedicum ^*  (Finland)

^e YAMAGATA UNIVERSITY   (Japan)

^f UNIVERSITY OF HELSINKI   (Finland)

^g ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^h COXA Hospital for Joint Replacement ^*  (Finland)

Author keywords

Fibroblast activation; Macrophage; Necrosis; RANKL; Scavenging; Total ankle replacement

Indexed keywords

CD163 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANKLE ARTHROPLASTY; ARTICLE; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; FOREIGN BODY REACTION; GIANT CELL; HUMAN; HUMAN TISSUE; MACROPHAGE; MALE; MECHANICAL STRESS; MESENCHYME CELL; OSTEOCLAST; OSTEOLYSIS; PROSTHESIS FAILURE; SYNOVIUM; TISSUE NECROSIS; TISSUE REACTION; VASCULAR ENDOTHELIUM;

AGED; ANKLE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTHROPLASTY, REPLACEMENT, ANKLE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OSTEOLYSIS; PROSTHESES AND IMPLANTS; PROSTHESIS FAILURE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CELL SURFACE;

EID: 84864774523     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.05.007     Document Type: Article

References (49)

1. Gougoulias N.E., Khanna A., Maffulli N. History and evolution in total ankle arthroplasty. Br Med Bull 2009, 89:111-151.
2. Wood P.L., Karski M.T., Watmough P. Total ankle replacement: the results of 100 mobility total ankle replacements. J Bone Joint Surg Br 2010, 92:958-962.
3. Besse J.L., Colombier J.A., Asencio J., Bonnin M., Gaudot F., Jarde O., et al. l'AFCP. Total ankle arthroplasty in France. Orthop Traumatol Surg Res 2010, 96:291-303.
4. van den Heuvel A., Van Bouwel S., Dereymaeker G. Total ankle replacement. Design evolution and results. Acta Orthop Belg 2010, 76:150-161.
5. Skytta E., Koivu H., Eskelinen A., Ikävalko M., Paavolainen P., Remes V. Total ankle replacement: a population-based study of 515 cases from the Finnish Arthroplasty Register. Acta Orthop 2010, 81:114-118.
6. Henricson A., Skoog A., Carlsson Å. The Swedish Ankle Arthroplasty Register. An analysis of 531 arthroplasties between 1993 and 2005. Acta Orthop 2007, 78:569-574.
7. Labek G., Klaus H., Schlichther R. Revision rates after total ankle arthroplasty in sample-based clinical studies and national registries. Foot Ankle Int 2011, 32:740-745.
8. Henricson A., Nilsson J.-Å., Carlsson Å. 10-year survival of total ankle arthroplasties. A report on 780 cases from the Swedish Ankle Register. Acta Orthop 2011, 82:655-659.
9. Haddad S.L., Coetzee J.C., Estok R., Fahrbach K., Banel D., Nalysnyk L. Intermediate and long-term outcomes of total ankle arthroplasty and ankle arthrodesis. A systematic review of the literature. J Bone Joint Surg Am 2007, 89:1899-1905.
10. Koivu H., Kohonen I., Sipola E., Alanen K., Vahlberg T., Tiusanen H. Severe periprosthetic osteolytic lesions after the Ankle Evolutive System total ankle replacement. J Bone Joint Surg Br 2009, 91-B:907-914.
11. Rodriguez D., Bevernage B.D., Maldague P., Deleu P.A., Tribak K., Leemrijse T. Medium term follow-up of the AES ankle prosthesis: high rate of asymptomatic osteolysis. Foot Ankle Surg 2010, 16:54-60.
12. Kokkonen A., Ikävalko M., Tiihonen R., Kautiainen H., Belt E.A. High rate of osteolytic lesions in medium-term followup after the AES total ankle replacement. Foot Ankle Int 2011, 32:168-175.
13. Mandelin J., Li T.F., Liljeström M., Kroon M.E., Hanemaaijer R., Santavirta S., et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg Br 2003, 85:1196-1201.
14. Mandelin J., Li T.F., Hukkanen M., Liljeström M., Salo J., Santavirta S., et al. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. J Rheumatol 2005, 32:713-720.
15. Goodman S.B., Gómez Barrena E., Takagi M., Konttinen Y.T. Biocompatibility of total joint replacements. A review. J Biomed Mater Res A 2009, 90:603-618.
16. Konttinen Y.T., Zhao D., Beklen A., Ma G., Takagi M., Kivelä-Rajamäki M., et al. The microenvironment around total hip replacement prostheses. Clin Orthop Relat Res 2005, 430:28-38.
17. Santavirta S., Konttinen Y.T., Bergroth V., Eskola A., Tallroth K., Lindholm T.S. Aggressive granulomatous lesions associated with hip arthroplasty. Immunopathological studies. J Bone Joint Surg Am 1990, 72-A:252-258.
18. Santavirta S., Hoikka V., Eskola A., Konttinen Y.T., Paavilainen T., Tallroth K. Aggressive granulomatous lesions in cementless total hip arthroplasty. J Bone Joint Surg Br 1990, 72-B:980-984.
19. Huk O.L., Catelas I., Mwale F., Antoniou J., Zukor D.J., Petit A. Induction of apoptosis and necrosis by metal ions in vitro. J Arthroplasty 2004, 19(Suppl. 3):84-87.
20. Mahendra G., Pandit H., Kliskey K., Murray D., Gill H.S., Athanasou N. Necrotic and inflammatory changes in metal-on-metal resurfacing hip arthroplasties. Relation to implant failure and pseudotumor formation. Acta Orthop 2009, 80:653-659.
21. Brown C., Williams S., Tipper J.L., Fisher J., Ingham E. Characterisation of wear particles produced by metal on metal and ceramic on metal hip prostheses under standard and microseparation simulation. J Mater Sci Mater Med 2007, 18:819-827.
22. Willert H.G., Buchhorn G.H., Fayyazi A., Flury R., Windler M., Köster G., et al. Metal-on-metal bearings and hypersensitivity in patients with artificial hip joints. A clinical and histomorphological study. J Bone Joint Surg Am 2005, 87:28-36.
23. Pandit H., Vlychou M., Whitwell D., Crook D., Luqmani R., Ostlere S., et al. Necrotic granulomatous pseudotumours in bilateral resurfacing hip arthoplasties: evidence for a type IV immune response. Virchows Arch 2008, 453:529-534.
24. Giebel G.D., Meyer C., Koebke J., Giebel G. The arterial supply of the ankle joint and its importance for the operative fracture treatment. Surg Radiol Anat 1997, 19:231-235.
25. Kärrholm J., Borssen B., Lowenhielm G., Snorrason F. Does early micromotion of femoral stem prostheses matter? 4-7-year stereoradiographic follow-up of 84 cemented prostheses. J Bone Joint Surg Br 1994, 76:912-917.
26. Stadelmann V.A., Terrier A., Pioletti D.P. Microstimulation at the bone-implant interface upregulates osteoclast activation pathways. Bone 2008, 42:358-364.
27. van der Vis H.M., Aspenberg P., de Kleine R., Tigchelaar W., van Noorden C.J.J. Short periods of oscillating fluid pressure directed at a titanium-bone interface in rabbits lead to bone lysis. Acta Orthop Scand 1998, 69:5-10.
28. Van Der Vis H.M., Aspenberg P., Marti R.K., Tigchelaar W., van Noorden C.J. Fluid pressure causes bone resortion in a rabbit model of prosthetic loosening. Clin Orthop Relat Res 1998, 350:201-208.
29. Aspenberg P., van der Vis H. Fluid pressure may cause periprosthetic osteolysis. Particles are not the only thing. Acta Orthop Scand 1998, 69:1-4.
30. Hendrix R.W., Wixson R.L., Rana N.A., Rogers L.F. Arthrography after total hip arthroplasty: a modified technique used in the diagnosis of pain. Radiology 1983, 148:647-652.
31. Robertsson O., Wingstrand H., Kesteris U., Jonsson K., Önnerfalt R. Intracapsular pressure and loosening of hip prostheses. Preoperative measurements in 18 hips. Acta Orthop Scand 1997, 68:231-234.
32. Pyevich M.T., Saltzman C.L., Callaghan J.J., Alvine F.G. Total ankle arthroplasty: a unique design. Two to twelve-year follow-up. J Bone Joint Surg Am 1998, 80:1410-1420.
33. Wood P.L., Deakin S. Total ankle replacement. The results in 200 ankles. J Bone Joint Surg Br 2003, 85:334-341.
34. Knecht S.I., Estin M., Callaghan J.J., Zimmerman M.B., Alliman K.J., Alvine F.G., et al. The Agility total ankle arthroplasty. Seven to sixteen-year follow-up. J Bone Joint Surg Am 2004, 86:1161-1171.
35. Valderrabano V., Hintermann B., Dick W. Scandinavian total ankle replacement: a 3.7-year average followup of 65 patients. Clin Orthop Relat Res 2004, 424:47-56.
36. Doets H.C., Brand R., Nelissen R.G. Total ankle arthroplasty in inflammatory joint disease with use of two mobile-bearing designs. J Bone Joint Surg Am 2006, 88:1272-1284.
37. Schutte B.G., Louwerens J.W. Short-term results of our first 49 Scandanavian total ankle replacements (STAR). Foot Ankle Int 2008, 29:124-127.
38. Mackiewicz Z., Rimkevicius A., Petersen J., Andersen C.B., Dudek E., Vytrasova M., et al. Macrophages overloaded with tissue debris in Wegener's granulomatosis. Ann Rheum Dis 2005, 64:1229-1232.
39. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
40. Takagi M., Tamaki Y., Hasegawa H., Takakubo Y., Konttinen L., Tiainen V.M., et al. Toll-like receptors in the interface membrane around loosening total hip replacement implants. J Biomed Mater Res A 2007, 81:1017-1026.
41. Pajarinen J., Cenni E., Savarino L., Gomez-Barrena E., Tamaki Y., Takagi M., et al. Profile of toll-like receptor-positive cells in septic and aseptic loosening of total hip arthroplasty implants. J Biomed Mater Res A 2010, 94:84-92.
42. Li T.F., Mandelin J., Hukkanen M., Lassus J., Sandelin J., Santavirta S., et al. Dendritic cells in rheumatoid synovial membrane after total removal of the hyaline articular cartilage. Rheumatology 2002, 41:319-323.
43. Li T.F., Santavirta S., Waris V., Lassus J., Lindroos L., Xu J.W., et al. No lymphokines in T-cells around loosened hip prostheses. Acta Orthop Scand 2001, 72:241-247.
44. Hilding M., Aspenberg P. Postoperative clodronate decreases prosthetic migration. 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthop 2006, 77:912-916.
45. Hilding M., Aspenberg P. Local perioperative treatment with a bisphosphonate improves the fixation of the total knee prosthesis. A randomized, double-blind radiostereometric study of 50 patients. Acta Orthop 2006, 77:912-916.
46. Friedl G., Radl R., Stihsen C., Rehak P., Aigner R., Windhager R. The effect of single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am 2009, 91:274-281.
47. Sköldenberg O.G., Salemyr M.O., Bodén H.S., Ahl T.E., Adolphson P.Y. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty. A randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am 2011, 93:1857-1864.
48. Black D.M., Delmas P.D., eastell R., Reid I.R., Boonen S., Cauley J.A., et al. HORIZON Pivotal Fracture Trial, once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
49. Lo J.C., O'Ryan F.S., Gordon N.P., Yang J., Hui R.L., Martin D., et al. Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators, prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010, 68:243-253.